Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: A randomized study of two different schedules of oxaliplatin

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 1, 2008, Pages 105-111

  Petrioli, Roberto ^a   Pascucci, Alessandra ^a   Francini, Edoardo ^a   Marsili, Stefania ^a   Sciandivasci, Angela ^a   Tassi, Rossana ^a   Civitelli, Serenella ^a   Tanzini, Gabriello ^a   Lorenzi, Marco ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACUTE DISEASE; ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISTAL PARESTHESIA; DOSE RESPONSE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS;

EID: 34848846310     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0454-3     Document Type: Article

References (27)

1. De Gramont A, Figer A, Seymour M, et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
2. Andrè T, Boni C, Mounedji-Boudiaf L, Navarro M, et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351
3. Louvet C, Andre T, Tigaud JM, et al (2004) Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20:4543-4548
4. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al (2004) Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658-663
5. Leong T (2005) Chemotherapy and radiotherapy in the management of gastric cancer. Curr Opin Gastroenterol 21:633-635
6. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774
7. Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 4:5-13
8. Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29(suppl 15):11-20
9. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053-1071
10. Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13-22
11. Giacchetti S, Perpoint B, Zigani R, et al (2000) Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147
12. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(suppl 15):21-33
13. Maindrault-Goebel F, de Gramont A, Louvet C, et al (2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX7). Eur J Cancer 37:1000-1005
14. Goldstein D, Mitchell P, Michael M, et al (2005) Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer 92:832-837
15. Kweekel DM, Gelderblom H, Guchelaar H-J (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31:90-105
16. Moxley RT III (2000) Channellopathies. Curr Treat Options Neurol 2:31-47
17. Bruguerolle B (1998) Chronopharmacokinetics: current status. Clin Pharmacokinet 35:83-94
18. Levi F, Zidani R, Misset JL, et al (1997) Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686
19. Levi F, Misset JL, Brienza S, et al (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900
20. Gamelin L, Boisdron-Celle, Delva R, et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061
21. Cascinu S, Catalano V, Cordella L, et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomised, double-blind, pacebo-controlled trial. J Clin Oncol 20:3478-3483
22. Wong GY, Michalak JC, Sloan JA, et al (2005) A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a north central cancer treatment group study. J Clin Oncol 23(Suppl 16):Abstract 8001
23. Mitchell PL, Goldstein D, Michael M, et al (2006) Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 6:146-151
24. Petrioli R, Sabatino M, Fiaschi AI, et al (2004) UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer 90:306-309
25. Tournigand C, Cervantes A, Figer A, et al (2006) OPTIMOX1: a randomized study of FOLFOX 4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer- a GERCOR study. J Clin Oncol 24:394-400
26. Maindrault-Goebel F, Lledo G, Chibaudel B, et al (2006) OPTIMOX2, a large randomised phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study ASCO 24:3504
27. Petrioli R, Paolelli L, Marsili S, et al (2006) FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology